Skip to Content

Drug Interactions between Kalydeco and Orkambi

This report displays the potential drug interactions for the following 2 drugs:

  • Kalydeco (ivacaftor)
  • Orkambi (ivacaftor/lumacaftor)

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Kalydeco and Orkambi. This does not necessarily mean no interactions exist. Always consult your healthcare provider.


A total of 369 drugs are known to interact with Kalydeco.


A total of 457 drugs are known to interact with Orkambi.

Drug and food interactions


ivacaftor food

Applies to: Kalydeco (ivacaftor) and Orkambi (ivacaftor / lumacaftor)

Ivacaftor should be taken with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products to help with its absorption. Do not consume grapefruit juice or any food that contains grapefruit or Seville oranges during treatment with ivacaftor unless directed otherwise by your doctor. Grapefruit juice can significantly increase the blood levels of ivacaftor. This may increase the risk and/or severity of serious side effects such as liver damage. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.


Cftr modulators

Therapeutic duplication

The recommended maximum number of medicines in the 'CFTR modulators' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'CFTR modulators' category:

  • Kalydeco (ivacaftor)
  • Orkambi (ivacaftor/lumacaftor)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.